Our Science

Platform

Pipeline

Partnerships

Company

Contact

What's happening.

FEATURED

Read the latest.

Pharma firms buy into promise of AI shortcut to designing new drugs

Read the article

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

Read the article

Engineering the key. Interview with Murat

Read the article

Pharma firms buy into promise of AI shortcut to designing new drugs

Read the article

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

Read the article

Engineering the key. Interview with Murat

Read the article

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein-Coupled Receptors
Read the article
Advances in Therapeutic Antibody Discovery and Development Targeting G Protein-Coupled Receptors
Read the article
Advances in Therapeutic Antibody Discovery and Development Targeting G Protein-Coupled Receptors
Read the article

all news

Exclusive: AI biotech Antiverse raises $9.3M Series A

3/3/26

Overcoming the Challenges of AI Antibody Analysis(Ben)

2/4/26

Why we partnered with Nxera?

12/28/24

Pharma firms buy into promise of AI shortcut to designing new drugs

11/6/24

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

11/5/24

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

10/16/23

Better biologics for the toughest targets.

Technology

Company

Engage

©2026 Antiverse. All rights reserved.

Better biologics for the toughest targets.

Technology

Company

Engage

©2026 Antiverse. All rights reserved.

Better biologics for the toughest targets.

Technology

Company

Engage

©2026 Antiverse. All rights reserved.